Similar articles for PMID: 22912864

Year	Number of Results
2003	1
2004	1
2005	3
2006	4
2008	1
2009	1
2010	3
2011	13
2012	19
2013	18
2014	14
2015	12
2016	12
2017	16
2018	12
2019	7
2020	3
2021	8
2022	12
2023	5
2024	0

1

Novel somatic mutations to PI3K pathway genes in metastatic melanoma.

Shull AY, Latham-Schwark A, Ramasamy P, Leskoske K, Oroian D, Birtwistle MR, Buckhaults PJ. Shull AY, et al. PLoS One. 2012;7(8):e43369. doi: 10.1371/journal.pone.0043369. Epub 2012 Aug 17. PLoS One. 2012. PMID: 22912864 Free PMC article.

2

Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.

Lázár V, Ecsedi S, Vízkeleti L, Rákosy Z, Boross G, Szappanos B, Bégány A, Emri G, Adány R, Balázs M. Lázár V, et al. Melanoma Res. 2012 Jun;22(3):202-14. doi: 10.1097/CMR.0b013e328352dbc8. Melanoma Res. 2012. PMID: 22456166 Free article.

3

Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.

Gao HW, Tsai WC, Perng CL, Wang WM, Chiang CP. Gao HW, et al. Eur J Dermatol. 2018 Aug 1;28(4):509-518. doi: 10.1684/ejd.2018.3359. Eur J Dermatol. 2018. PMID: 30325319

4

[Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].

Lázár V. Lázár V. Magy Onkol. 2013 Jun;57(2):96-9. Epub 2013 May 20. Magy Onkol. 2013. PMID: 23795354 Free article. Hungarian.

5

Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.

Ogawa K, Sun C, Horii A. Ogawa K, et al. Oncol Rep. 2005 Dec;14(6):1481-5. Oncol Rep. 2005. PMID: 16273242

6

Targeted Therapy for Melanomas Without BRAF V600 Mutations.

Menzer C, Hassel JC. Menzer C, et al. Curr Treat Options Oncol. 2022 Jun;23(6):831-842. doi: 10.1007/s11864-022-00946-4. Epub 2022 Apr 5. Curr Treat Options Oncol. 2022. PMID: 35380338 Free PMC article. Review.

7

BRAF V600 mutations and pathological features in Japanese melanoma patients.

Yamazaki N, Tanaka R, Tsutsumida A, Namikawa K, Eguchi H, Omata W, Oashi K, Ogawa T, Hayashi A, Nakamura N, Tsuta K. Yamazaki N, et al. Melanoma Res. 2015 Feb;25(1):9-14. doi: 10.1097/CMR.0000000000000091. Melanoma Res. 2015. PMID: 25051202 Free PMC article.

8

Clinicopathological features and clinical outcomes associated with TP53 and BRAF^N^on-^V⁶⁰⁰ mutations in cutaneous melanoma patients.

Kim DW, Haydu LE, Joon AY, Bassett RL Jr, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Kim DW, et al. Cancer. 2017 Apr 15;123(8):1372-1381. doi: 10.1002/cncr.30463. Epub 2016 Dec 2. Cancer. 2017. PMID: 27911979 Free PMC article.

9

BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.

Yaman B, Kandiloğlu G, Akalin T. Yaman B, et al. Am J Dermatopathol. 2016 Feb;38(2):113-20. doi: 10.1097/DAD.0000000000000404. Am J Dermatopathol. 2016. PMID: 26630683

10

Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.

Cejalvo JM, Pérez-Fidalgo JA, Ribas G, Burgués O, Mongort C, Alonso E, Ibarrola-Villava M, Bermejo B, Martínez MT, Cervantes A, Lluch A. Cejalvo JM, et al. Breast Cancer Res Treat. 2016 Nov;160(1):69-77. doi: 10.1007/s10549-016-3980-z. Epub 2016 Sep 14. Breast Cancer Res Treat. 2016. PMID: 27628192

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

149 results

Results by year